Abdul Mannan: Advancing VWF Activity Testing Beyond VWF:RCo in Clinical Laboratories
Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“Your VWF activity assay might be giving you the wrong answer.
And that wrong answer changes everything downstream.
VWF:RCo has been the workhorse of VWD testing for decades.
But here’s what the data actually shows:
- VWF:RCo imprecision sits around 9%. GPIb-based assays? Around 3.2%.
- Ristocetin-sensitive polymorphisms can falsely lower the activity:Ag ratio. That’s not biology. That’s assay noise.
- In diverse populations, this creates a predictable disadvantage. The same patient, different ethnicity, different result. That’s an equity problem.
Why does this matter so much?
The VWF activity result sits at the centre of the subtype algorithm. I
f that number drifts, everything drifts with it:
- Type 1 patients get pushed into a Type 2 work-up
- Unnecessary multimers, RIPA, genetics referrals follow
- DDAVP decisions and perioperative plans change
- Borderline cases get missed entirely
VWF:GPIbM offers a way out.
No ristocetin dependence.
No polymorphism distortion.
92% Type 2 sensitivity. 85.1% Type 1 specificity. Same 0.70 activity:Ag ratio threshold. Same diagnostic logic.
The message is simple: modernise the assay, preserve the pathway.
Both BSH 2024 and ASH/ISTH 2021 guidelines point the same direction.
But this isn’t just a reagent swap.
It’s a quality programme.
- Validation
- Reporting language
- Clinical education
- Post-go-live review
All need to land together.
I built an interactive guide to walk laboratories through this transition step by step.
- Assay comparison
- Decision algorithms
- Implementation framework
- Rhe evidence behind each choice
All in one place.
Has your lab made this switch yet?
What held you back, or what pushed you forward?”
Other posts featuring Abdul Mannan on Hemostasis Today.
-
Aug 4, 2026, 20:48New Real-World Data on Efanesoctocog Alfa From France – CRH French Reference Center for Hemophilia Lyon
-
Aug 4, 2026, 20:37Hisam Siddiqi: Haemoglobinopathy Basics – A Quick Guide to Thalassaemia
-
Aug 4, 2026, 20:36Ifeanyichukwu Ifechidere: AI May Soon Interpret Coagulation Results Better Than Some Healthcare Professionals
-
Aug 4, 2026, 20:35Ediga Naga Pradeep Kumar: Excited to Share My Latest Data Analytics Project – Stroke Risk Analysis Dashboard
-
Aug 4, 2026, 20:34Amar Shah: Improving Thrombolysis for Acute Stroke Through Quality Improvement
-
Aug 4, 2026, 20:33Federica Sepe: Are Biomarkers Finally Ready for Precision Stroke Medicine?
-
Aug 4, 2026, 20:10Kabir Olaniran: Sickle Cell Trait and Chronic Kidney Disease Risk
-
Aug 4, 2026, 19:57Toby Richards: Iron Deficiency Beyond Anaemia in Female Triathletes
-
Aug 4, 2026, 17:14Edward Lee Carter: Not Every Stroke on a DOAC Is a DOAC Failure